Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature... Read more.
Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting
New research demonstrates the emerging applications of Foundation Medicine’s liquid biopsy and monitoring portfolio Additional research investigates new biomarkers... Read more.
Booz Allen Hamilton Announces Fourth Quarter and Full Fiscal Year 2024 Results
MCLEAN, Va.–(BUSINESS WIRE)–$BAH–Booz Allen Hamilton Holding Corporation (NYSE: BAH), the parent company of management and technology consulting... Read more.
MyGuava and Visa Launch Collaborative Out Of Home Campaign in London
LONDON–(BUSINESS WIRE)–#allthingspayments–Guavapay, a global fintech company has announced its partnership with Visa, a world leader in digital... Read more.
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
– Late-breaking presentations for sebetralstat phase 3 KONFIDENT and KONFIDENT-S trials on Friday, May 31 – – Multiple real-world data presentations show that... Read more.
CMBM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Cambium Networks Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Cambium Networks Corporation... Read more.
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel... Read more.
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J.–(BUSINESS WIRE)–$OGN #denosumabbiosimilar–Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN)... Read more.
The Duckhorn Portfolio Announces Enhanced Distribution Relationships with Republic National Distributing Company and Breakthru Beverage Group
ST. HELENA, Calif.–(BUSINESS WIRE)–The Duckhorn Portfolio, Inc. (NYSE: NAPA) (the “Company”) announced today that it has entered into distribution... Read more.
National Grid Recognizes Runwise – Top ProNet Partner in 2023 For Energy Conservation
Runwise handled more energy controls projects than any other partner in the region. NEW YORK–(BUSINESS WIRE)–Runwise was celebrated for outstanding achievements... Read more.